Fundraising Fox
+ND Capital
Venture capitalWoodside · Seed–Late Stage · 17 people tracked
Also known as NANODIMENSION AG · NANODIMENSION, INC.
Find your way into +ND Capital
1,719 people in our graph share verified history with the +ND Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
+ND Capital invests in companies built on breakthroughs at the nanoscale, applying deep scientific expertise to distinguish genuine innovation from speculation. Founded on the conviction that significant technological advances would emerge from nanotechnology, the firm combines European scientific roots with a strong presence in the US venture ecosystem, particularly Boston and Silicon Valley, where it identifies compelling investment opportunities across energy, materials, therapeutics, and advanced technology.
Source: firm website, verified Sep 29, 2026.
Team · 17 people
from the firm's website & public directories
Founder mafia
2 people who came through +ND Capital went on to found or lead other companies.
What they invest in
from 34 of 43 portfolio companiesBiotech ×30Healthtech ×15Deep Tech ×12Medical Devices ×10AI & Machine Learning ×6Digital Health ×3Hardware ×3Semiconductors ×3
HQs:United States×21Switzerland×3Denmark×2United Kingdom×2
Who they back
founder profiles across 17 portfolio companiesFounding team size:solo founder×72 founders×63 founders×24+ founders×2
Where their founders studiedfrom 15 founders with education data
University of California, Berkeley ×2University of California, San Francisco ×2
What their founders studiedfrom 16 founders with field-of-study data
Engineering ×9Life Sciences ×5Chemistry ×2Computer Science ×2Medicine ×2Physics ×2
Where their founders worked beforefrom 19 founders with career history
Stanford University ×3CHUV | Lausanne university hospital ×2Seer Biosciences ×2The University of Tokyo ×2UC Berkeley ×2
Investments · 43 tracked
founders shown can be your intro pathBy year:2026 · 22024 · 12023 · 12022 · 12021 · 42019 · 12018 · 22017 · 12016 · 32014 · 22012 · 12009 · 122 dated
AstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.
Cambridge, GB
Co-investorsvenBio Partners
Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases.
BiotechHealthtechWatertown, US
Metin Kurtoglu(Executive Officer)Omid Farokhzad(Director)Chris Jewell(Executive Officer)inCarsten Brunn(President, CEO & Chairman of the Board)inEmily English(Executive Officer)inBlaine Davis(Executive Officer)in
Co-investorsK2 HealthVenturesMaryland TEDCOSchooner CapitalTEDCOPolaris PartnersRUSNANO
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily M. Leproust(Chief Executive Officer and Chair of the Board)inEmily Leproust, PhD(CEO and Co-Founder of Twist)Patrick Finn(President and Chief Operating Officer)in
Co-investors3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyATEL VenturesBay City CapitalBlack Opal Ventures+10 more
Emulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research.
BiotechDeep TechHealthtech
Donald Ingber(Scientific Founder, Board Member, Scientific Advisory Board Chairman)inDaniel Levner(Co-Founder & CTO)inJim Corbett(CEO, Board Member)inLorna Ewart(Chief Scientific Officer)in
Co-investorsNorthpond VenturesAlwyn CapitalFourth RealmStray Dog CapitalOS FundStarlight Ventures
Notify develops pharmaceutical treatments for women with diminished ovarian reserves by targeting dormant follicle activation through NRF2 pathway modulation.
BiotechDigital HealthFemTechHealthtechMedical DevicesAarhus, DK
Karin Lykke-Hartmann(Chief Executive Officer & Founder)
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
Co-investorsPureos Bioventures
Vandria is a pharmaceutical development company focused on translating scientific innovation into first-in-class therapeutics.
BiotechHealthtechLongevityMedical DevicesLausanne, CH
Patrick Aebischer(Co-founder)Pénélope Andreux(Head of Research (mitochondrial research and development))inKlaus Dugi(Chief Medical Officer / Medical Leadership)inPeter(Business Development & Entrepreneurship Leadership)Leila(Operations Leadership)Anke Post(Chief Medical Officer / Neuroscience Leadership)
Co-investorsDolby Family VenturesLevensohn Venture PartnersApollo Health Ventures
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investorsARCH Venture PartnersForbionVenrockFast Track InitiativeNextech InvestNovalis LifeSciences+2 more
BiotechNew York, US
Masoud Tavazoie(Chief Scientific Officer)David Darst(Chief Operating Officer)Isabel Kurth(Vice President - Research)
BoardShahram Seyedin-Noor(Executive Chairman)Nancy Chang(Director)
Board seatPeter Van Vlasselaer· per SEC Form D · $11M raise · filed Feb 2021
Co-investorsOceanpine CapitalSofinnova Partners
ALLInBio develops a precision immunology approach to identify and treat patients genetically predisposed to rapid progression of chronic inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsArtis Ventures
Amazentis is a Swiss longevity-biotech company that developed Mitopure, a proprietary high-purity form of the postbiotic Urolithin A shown in human trials to support mitochondrial health via mitophagy.
BiotechLongevityWellness & FitnessLausanne, CH
Co-investorsBold Capital Partners
Arc Therapeutics is a stealth-stage biopharmaceutical company developing medicines for central nervous system (CNS) conditions with high unmet medical needs.
BiotechHealthtech
Co-investorsV-Bio Ventures
Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.
BiotechDeep TechNew Materials
Jason Chin(Professor)
Co-investorsAmadeus Capital PartnersFine Structures VenturesGENERAL INCEPTIONLongeVCOMX VenturesPaladin Capital Group+2 more
Crocus Technology, now part of Allegro MicroSystems, develops XtremeSense TMR (Tunnel Magnetoresistance) magnetic sensing technology used in integrated current and position sensor ICs.
Co-investorsVentechVentech ChinaCEA InvestissementSofinnova Ventures
Cytoki is a biotech company developing IL-22-based therapeutics using lipidation technology to treat metabolic diseases such as obesity and type 2 diabetes, as well as conditions involving epithelial injury like inflammatory bowel disease.
BiotechHealthtechVærløse, DK
Rasmus Jorgensen(CEO & Founder)in
Co-investorsYsios CapitalSeventure Partners
Develops novel ocular therapies.
BiotechMorrisville, US
Ben Yerxa(Executive Officer)inEric Linsley(Executive Officer)in
BoardEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)
Co-investorsCanaan PartnersNew Enterprise Associates (NEA)Pappas CapitalARCH Venture PartnersIllumina VenturesOMX Ventures
Euphrates Vascular develops the Pulse NanoMED System, a nanoscale interventional medical device that uses magnetically guided iron-oxide nanoparticles to reach and disrupt distal vascular occlusions beyond the reach of wires and catheters.
BiotechHealthtechMedical DevicesSt. Louis, US
Troy Long(Executive Officer)Jeffrey Blair(Director)Tim Blair(Executive Officer)inEric Moessinger(Director)Robert Mitchell(Director)Thomas Hillman(Director)
Co-investorsMissouri Technology CorporationOSF VenturesView VenturesCultivation Capital
H55 develops certified electric propulsion systems and energy storage solutions for aviation, enabling aircraft manufacturers to transition to electric flight.
CleantechEnergyHardwareMobility & TransportationSion, CH
André Borschberg(Co-Founder and Executive Chairman)in
Co-investorsACE & CompanyTippet Venture Partners (Gp), Llc
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)inDaniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in
Co-investorsBroadview VenturesSofinnova PartnersApollo Health Ventures4see VenturesHumboldt
BiotechBoulder, US
Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)
BoardRoger Wyse(Director)inBryan Roberts(Director)in
Co-investorsForesite CapitaliGlobe PartnersKorysOak HC/FTOMX VenturesPaladin Capital Group+4 more
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investorsIllumina VenturesLongwall Venture Partners LLPM VenturesOMX VenturesARCH Venture Partners
Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsARCH Venture PartnersIllumina VenturesPerscitus LLPM VenturesOMX Ventures
Manus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing.
BiotechFoodTechNew MaterialsAugusta, US
Ajikumar Parayil(Executive Officer, Director)inAji Parayil(Co-founder)inGreg Stephanopoulos(Co-founder)
BoardJason Whaley(Director)inCarsten Boers(Director)inRichard Goldstein(Director)
Co-investorsCivilization Ventures Management, LlcEnergy Impact PartnersLiebenthal VenturesNelstone VenturesNXT VenturesPrefix Capital+2 more
RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.
BiotechEmeryville, US
Igor Khandros(Executive Officer, Director)
Co-investorsARCH Venture PartnersBluebird VenturesCraft VenturesFounders FundParadigmSam Altman+1 more
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Co-founder)inRamsey Homsany(Founder)in
Co-investorsAndreessen Horowitz8VCCarbon SiliconCatalio Capital Management, LPExplorer InvestmentsFifty Years+8 more
Orca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome.
BiotechDigital HealthHealthtechMedical DevicesCalifornia, US
Jeroen(Co-founder and President)Ivan Dimov(Executive Officer, Director)inNathaniel Fernhoff(Executive Officer, Director)in
BoardAlex Kolicich(Director)inJonathan MacQuitty(Director)in
Co-investors8VCDCVC (Data Collective)Felicis VenturesLightspeed Venture PartnersSeraph GroupAndreessen Horowitz
Partillion generates cell-cell interaction data using Nanovials that co-localize cells in defined microenvironments to measure signaling, activation, binding, and other responses, with live-cell recovery via standard flow cytometry.
AI & Machine LearningBiotechDeep TechLos Angeles, US
Dino Di Carlo(Director)inJoe de Rutte(Founder)inEric Moessinger(Director)in
BoardPaul Conley(Director)in
Co-investorsGENERAL INCEPTIONPaladin Capital GroupVertical Venture Partners
Serotiny designs cell therapies using custom software and lab techniques that allow it to design and test up to 10,000 therapeutic genes at once, aiming to speed up the discovery of treatments for cancers such as multiple myeloma, prostate cancer and lung cancer.
AI & Machine LearningBiotechHealthtechSan Francisco, US
Justin Farlow(Co-founder)inColin Farlow(Co-founder)Eric Moessinger(Director)in
Co-investors8VC
SiMa.ai designs silicon and software to enable machine learning inference at the edge, deployed in industrial, automotive, and autonomous systems rather than cloud environments.
AI & Machine LearningDeep TechHardwareSemiconductorsSan Jose, US
Krishna Rangasayee(Founder & CEO)in
Co-investorsAmplify PartnersWing
SPARK Microsystems develops ultra-wideband (UWB) wireless connectivity technology for applications including Physical AI, XR, audio, gaming, human interface, and IoT devices.
Deep TechHardwareIoTSemiconductors
Co-investorsSilicon CatalystCycle Capital
BiotechWatertown, US
Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Armon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)
Co-investorsGV (Google Ventures)Illumina VenturesInvusJDRF T1D FundQuark Venture Inc.Temasek+1 more
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples.
BiotechDeep TechMedical DevicesSanta Monica, US
Geoff Smith(Founder & CEO)inJason Betley(Chief Product Officer)in
Co-investorsOMX VenturesARCH Venture Partners
BiotechWatertown, US
Omid Farokhzad(Director)inRobert S. Langer, Jr.(Director)Omid C. Farokhzad(Director)inRobert S. Langer(Director)Andrew J. Fromkin(Executive Officer, Director)Leila Alland(Executive Officer)in
Co-investorsKendall Capital PartnersNew Enterprise Associates (NEA)
Visby offers an FDA-authorized at-home PCR test kit for women's sexual health that detects chlamydia, gonorrhea, and trichomoniasis from a single swab, delivering private results via a mobile app in about 30 minutes with included same-day telehealth for positive results.
ConsumerDigital HealthFemTechHealthtechMedical DevicesTokyo, US
Adam de la Zerda(Founder)in
Co-investors1809 CapitalAmplify PartnersArtiman VenturesG Vision CapitalJ-VenturesKhosla Ventures+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Blade TherapeuticsAmphivena TherapeuticsARMO BioSciencesBIND TherapeuticsNatron EnergySelecta BiosciencesSQZ Biotech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
3 IPOs · 1 acquisitions · showing 3AlumniNYSE: AZNCartesian Therapeutics (NASDAQ: RNAC)NASDAQ: RNACTwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companiesIPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Cartesian Therapeutics (NASDAQ: RNAC) | — | $14.00 | Jun 2016 | $9.4M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has +ND Capital made?
- +ND Capital has 43 tracked investments, 4 of which have exited, including 2 dated in the last 24 months.
- What stage does +ND Capital invest at?
- +ND Capital invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What is +ND Capital's typical check size?
- +ND Capital typically writes checks of $540K – $5.4M.
- What sectors does +ND Capital focus on?
- +ND Capital focuses on Biotech, Deep Tech, Energy, Hardware, Healthtech, New Materials, Semiconductors.
- Where is +ND Capital located?
- +ND Capital is headquartered in Woodside, US.
- Does +ND Capital lead rounds?
- Yes, +ND Capital leads investment rounds.
- Who does +ND Capital co-invest with?
- +ND Capital most often shares deals with ARCH Venture Partners, OMX Ventures, Paladin Capital Group, among 70 tracked co-investors.
Co-investors · 15
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Paladin Capital Group invests in early stage and growth companies developing cyber, AI and deep technologies that address security and resilience needs for commercial and government customers.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Cultivation Capital is a venture capital firm that invests in early-stage companies with the potential to transform how people live and work, backing them from Series Seed through Series B.
Seventure Partners is a European venture capital firm backing innovative companies across life sciences and digital technologies, with additional focus areas in sport & performance and the blue economy.
▶3 more co-investors
Firms observed investing alongside +ND Capital, from public investor directories. Shared companies are the overlap with +ND Capital's recorded portfolio.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Blindspot Ventures is an infrastructure-focused technology investment fund that backs founders building foundational platforms, systems, and technologies for critical industries.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Industrial Technology Investment Corporation is the venture capital arm of Taiwan's Industrial Technology Research Institute (ITRI), backing startups across multiple stages and sectors while providing access to ITRI's R&D resources.
Cowin Capital Group is a Chinese investment management firm with extensive experience investing in and exiting technology, healthcare, and industrial companies, many of which have gone public on Chinese and Hong Kong exchanges.